Sekundäre Diabetesformen / Typ-3-Diabetes

Literatur

• 1 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Report of the expert committee on the diagnosis and classification of diabetes mellitus.  Diabetes Care. 1997;  20 1183-1197
• 2 Fajans S S, Bell G I, Polonsky K S. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young.  NEJM. 2001;  345 971-980
• 3 Stumvoll M, Stefan N, Fritsche A et al. Diabetes mellitus. In: Lehnert H, Hrsg. Rationelle Diagnostik und Therapie in Endokrinologie, Stoffwechsel und Diabetes. Stuttgart: Thieme; 2009: 335–379
• 4 Hummel M, Vasseur F, Mathieu C et al. Two caucasian families with the hepatocyte nuclear factor-1alpha mutation Y218C.  Exp Clin Endocrinol Diabetes. 2007;  115 62-64
• 5 Moran A, Dunitz J, Nathan B et al. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality.  Diabetes Care. 2009;  32 1626-1631
• 6 Moran A, Pekow P, Grover P Cystic Fibrosis Related Diabetes Therapy Study Group et al.,. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial.  Diabetes Care. 2009;  32 1783-1788
• 7 Rizza R A, Mandarino L J, Gerich J E. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action.  J Clin Endocrinol Metab. 1982;  54 131-138
• 8 Biering H, Knappe G, Gerl H et al. [Prevalence of diabetes in acromegaly and Cushing’s disease].  Acta Medica Austriaca. 2000;  27 27-31
• 9 Arnaldi G, Mancini T, Polenta B et al. Cardiovascular risk in Cushing’s syndrome.  Pituitary. 2004;  7 253-256
• 10 Newell-Price J, Bertagna X, Grossman A B et al. Cushing’s syndrome.  Lancet. 2006;  367 1605-1617
• 11 Findling J W, Raff H. Cushing’s Syndrome: important issues in diagnosis and management.  J Clin Endocrinol Metab. 2006;  91 3746-3753
• 12 Whitworth J A, Williamson P M, Mangos G et al. Cardiovascular consequences of cortisol excess.  Vasc Health Risk Manag. 2005;  1 291-299
• 13 Colao A, Auriemma R S, Galdiero M et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.  J Clin Endocrinol Metab. 2009;  94 3746-3756
• 14 Ali O, Banerjee S, Kelly D F et al. Management of type 2 diabetes mellitus associated with pituitary gigantism.  Pituitary. 2007;  10 359-364
• 15 Møller N, Jørgensen J O. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects.  Endocr Rev. 2009;  30 152-177
• 16 Kasayama S, Otsuki M, Takagi M et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients.  Clin Endocrinol (Oxf). 2000;  52 549-555
• 17 Resmini E, Minuto F, Colao A et al. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.  Acta Diabetol. 2009;  46 85-95
• 18 Yavuz D G, Yüksel M, Deyneli O et al. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients.  Clin Endocrinol (Oxf). 2004;  61 515-521
• 19 Gupta A K, Dahlof B, Dobson J Anglo-Scandinavian Cardiac Outcomes Trial Investigators et al.,. Determinants of new-onset diabetes among 19 257 ypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.  Diabetes Care. 2008;  31 982-988
• 20 Elliott W J, Meyer P M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.  Lancet. 2007;  369 201-207
• 21 NAVIGATOR Study Group . Effect of valsartan on the incidence of diabetes and cardiovascular events.  N Engl J Med. 2010;  362 1477-1490
• 22 Basile J N. Antihypertensive therapy, new-onset diabetes, and cardiovascular disease.  Int J Clin Pract. 2009;  63 656-666
• 23 Andersohn F, Schade R, Suissa S et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus.  Am J Psychiatry. 2009;  166 591-598
• 24 De Hert M, Schreurs V, Vancampfort D et al. Metabolic syndrome in people with schizophrenia: a review.  World Psychiatry. 2009;  8 15-22
• 25 American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes.  Diabetes Care. 2004;  27 596-601
• 26 Toro C, Jacobowitz D M, Hallett M. Stiff-Man Syndrome.  Sem Neurol. 1994;  14 154-158
• 27 Blum P, Jankovic J. Siff-Person Syndrome. An Autoimmune Disease.  Mov Disord. 1991;  6 2-20
• 28 Solimena M, Folli F, Aparisi R et al. Autoantibodies to GABA-ergic Neurones and Pancreatic Beta Cells in Stiff-Man Syndrome.  N Engl J Med. 1990;  322 1555-1560
• 29 Baekkeskov S, Aanstoot H J, Christgau S et al. Identification of the 64 k autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamatic acid decarboxylase.  Nature. 1990;  347 151-156
• 30 Hummel M, Durinovic-Bello I, Bonifacio E et al. Humoral and Cellular Immune Parameters before and during immunsuppressive therapy of a patient with Stiff-Man Syndrom and IDDM.  J Neurol Neurosurg Psychiatry. 1998;  65 204-208
• 31 Rohrer T R, Hennes P, Thon A DPV Initiative et al.,. Down’s syndrome in diabetic patients aged < 20 years: an analysis of metabolic status, glycaemic control and autoimmunity in comparison with type 1 diabetes.  Diabetologia. 2010;  53 1070-1075